VSports最新版本 - Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ
- PMID: 26291673
- DOI: 10.1001/jamaoncol.2015.2510
Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ
Abstract
Importance: Women with ductal carcinoma in situ (DCIS), or stage 0 breast cancer, often experience a second primary breast cancer (DCIS or invasive), and some ultimately die of breast cancer. VSports手机版.
Objective: To estimate the 10- and 20-year mortality from breast cancer following a diagnosis of DCIS and to establish whether the mortality rate is influenced by age at diagnosis, ethnicity, and initial treatment received. V体育安卓版.
Design, setting, and participants: Observational study of women who received a diagnosis of DCIS from 1988 to 2011 in the Surveillance, Epidemiology, and End Results (SEER) 18 registries database. Age at diagnosis, race/ethnicity, pathologic features, date of second primary breast cancer, cause of death, and survival were abstracted for 108,196 women V体育ios版. Their risk of dying of breast cancer was compared with that of women in the general population. Cox proportional hazards analysis was performed to estimate the hazard ratio (HR) for death from DCIS by age at diagnosis, clinical features, ethnicity, and treatment. .
Main outcomes and measures: Ten- and 20-year breast cancer-specific mortality VSports最新版本. .
Results: Among the 108 196 women with DCIS, the mean (range) age at diagnosis of DCIS was 53. 8 (15-69) years and the mean (range) duration of follow-up was 7. 5 (0-23. 9) years. At 20 years, the breast cancer-specific mortality was 3. 3% (95% CI, 3. 0%-3. 6%) overall and was higher for women who received a diagnosis before age 35 years compared with older women (7. 8% vs 3. 2%; HR, 2. 58 [95% CI, 1 V体育平台登录. 85-3. 60]; P < . 001) and for blacks compared with non-Hispanic whites (7. 0% vs 3. 0%; HR, 2. 55 [95% CI, 2. 17-3. 01]; P < . 001). The risk of dying of breast cancer increased after experience of an ipsilateral invasive breast cancer (HR, 18. 1 [95% CI, 14. 0-23. 6]; P < . 001). A total of 517 patients died of breast cancer following a DCIS diagnosis (mean follow-up, 7. 5 [range, 0-23. 9] years) without experiencing an in-breast invasive cancer prior to death. Among patients who received lumpectomy, radiotherapy was associated with a reduction in the risk of ipsilateral invasive recurrence at 10 years (2. 5% vs 4. 9%; adjusted HR, 0. 47 [95% CI, 0. 42-0. 53]; P < . 001) but not of breast cancer-specific mortality at 10 years (0. 8% vs 0. 9%; HR, 0. 86 [95% CI, 0. 67-1. 10]; P = . 22). .
Conclusions and relevance: Important risk factors for death from breast cancer following a DCIS diagnosis include age at diagnosis and black ethnicity. The risk of death increases after a diagnosis of an ipsilateral second primary invasive breast cancer, but prevention of these recurrences by radiotherapy does not diminish breast cancer mortality at 10 years. VSports注册入口.
Comment in (V体育平台登录)
-
Rethinking the Standard for Ductal Carcinoma In Situ Treatment.JAMA Oncol. 2015 Oct;1(7):881-3. doi: 10.1001/jamaoncol.2015.2607. JAMA Oncol. 2015. PMID: 26291410 No abstract available.
-
V体育2025版 - Death from ductal carcinoma in situ is very low except in young and black women, US data show.BMJ. 2015 Aug 20;351:h4555. doi: 10.1136/bmj.h4555. BMJ. 2015. PMID: 26297742 No abstract available.
-
DCIS does not need treatment... really?Breast Cancer Res Treat. 2015 Nov;154(1):1-4. doi: 10.1007/s10549-015-3606-x. Breast Cancer Res Treat. 2015. PMID: 26476724 No abstract available.
-
Treatment and Long-term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ.JAMA Oncol. 2016 Mar;2(3):396. doi: 10.1001/jamaoncol.2015.4854. JAMA Oncol. 2016. PMID: 26967178 No abstract available.
-
Effects of Standard Treatments for Ductal Carcinoma In Situ-Making Informed Choices.JAMA Oncol. 2016 Mar;2(3):396-7. doi: 10.1001/jamaoncol.2015.4857. JAMA Oncol. 2016. PMID: 26967179 No abstract available.
-
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ.JAMA Oncol. 2016 Mar;2(3):397-8. doi: 10.1001/jamaoncol.2015.4860. JAMA Oncol. 2016. PMID: 26967180 Free PMC article. No abstract available.
-
Treatment Recommendations for Patients With a Diagnosis of Ductal Carcinoma In Situ.JAMA Oncol. 2016 Mar;2(3):398. doi: 10.1001/jamaoncol.2015.4863. JAMA Oncol. 2016. PMID: 26967181 No abstract available.
-
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ.JAMA Oncol. 2016 Mar;2(3):398-9. doi: 10.1001/jamaoncol.2015.4866. JAMA Oncol. 2016. PMID: 26967182 No abstract available.
-
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ.JAMA Oncol. 2016 Mar;2(3):399. doi: 10.1001/jamaoncol.2015.4872. JAMA Oncol. 2016. PMID: 26967183 No abstract available.
-
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ.JAMA Oncol. 2016 Mar;2(3):399-400. doi: 10.1001/jamaoncol.2015.4875. JAMA Oncol. 2016. PMID: 26967184 No abstract available.
-
Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.JAMA Oncol. 2016 Mar;2(3):400-1. doi: 10.1001/jamaoncol.2015.4878. JAMA Oncol. 2016. PMID: 26967185 No abstract available.
"V体育安卓版" Publication types
- "VSports在线直播" Actions
MeSH terms (V体育安卓版)
- Actions (V体育官网)
- VSports手机版 - Actions
- VSports手机版 - Actions
- Actions (VSports注册入口)
- "V体育ios版" Actions
- Actions (V体育2025版)
- VSports注册入口 - Actions
- Actions (VSports手机版)
- Actions (V体育官网入口)
- V体育官网 - Actions
- VSports最新版本 - Actions
- "VSports app下载" Actions
- "VSports在线直播" Actions
- "VSports" Actions
- Actions (V体育ios版)
- "VSports app下载" Actions
- "V体育官网" Actions
- Actions (VSports最新版本)
- Actions (VSports)
LinkOut - more resources
Full Text Sources
"V体育官网入口" Other Literature Sources
"VSports最新版本" Medical